Clinical Trials on Peripheral T/NK-cell Lymphoma in Netherlands

Total 223 results

Kyowa Hakko Kirin Pharma, Inc.

Completed

Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)

Peripheral T-Cell Lymphoma

France, United Kingdom, Netherlands, Denmark, Italy, Spain
Daiichi Sankyo

Active, not recruiting

Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

Relapsed/Refractory Peripheral T-Cell Lymphoma | Adult T Cell Leukemia/Lymphoma

United States, Spain, Japan, United Kingdom, Korea, Republic of, France, Italy, Australia, Canada, Germany, Netherlands, Taiwan
Millennium Pharmaceuticals, Inc.

Completed

Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma

Refractory Peripheral T-Cell Lymphoma | Relapsed Peripheral T-Cell Lymphoma

United States, France, Italy, Poland, United Kingdom, Belgium, Germany, Spain, Belarus, Israel, Portugal, Bulgaria, Turkey, Canada, New Zealand, Peru, Brazil, Russian Federation, Chile, Puerto Rico, Australia, Austria, Hungary, Nether... and more
Innate Pharma

Completed

Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)

Cutaneous T-Cell Lymphoma

United States, France, Netherlands, United Kingdom
Centocor Ortho Biotech Services, L.L.C.

Completed

Observational Study on the Occurrence of Hepatosplenic T-cell Lymphoma in Patients of Netherlands

Hepatosplenic T-cell Lymphoma

Netherlands
Spectrum Pharmaceuticals, Inc
Onxeo

Completed

Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)

Peripheral T-cell Lymphoma

United States, Belgium, United Kingdom, Germany, Spain, Poland, Israel, Netherlands, Canada, Croatia, Denmark, France, Hungary, Italy, Russian Federation, Slovakia, South Africa
Kyowa Kirin, Inc.

Completed

Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL

Cutaneous T-Cell Lymphoma

United States, Spain, France, Australia, Switzerland, United Kingdom, Japan, Denmark, Germany, Italy, Netherlands
Mundipharma Research Limited

Active, not recruiting

Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

Multiple Myeloma | Hodgkin's Lymphoma | Hematological Malignancies | Cutaneous T Cell Lymphoma

France, United States, Netherlands, Spain, Switzerland, Germany, Italy
Amgen

Completed

Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease

Type II Refractory Celiac Disease (RCD-II) | In-situ Small Bowel T-cell Lymphoma

Spain, United States, Finland, France, Netherlands
Centre for Human Drug Research, Netherlands
Recordati Rare Diseases

Completed

Deep Phenotyping of Cutaneous T Cell Lymphoma, Type Mycosis Fungoides

Mycosis Fungoides

Netherlands
Centre for Human Drug Research, Netherlands
Leiden University Medical Center; Micreos

Enrolling by invitation

Skin Barrier and Microbiome of CTCL Patients

Lymphoma, T-Cell, Cutaneous

Netherlands
Aarhus University Hospital
GCP-unit at Aarhus University Hospital, Aarhus, Denmark

Completed

Alemtuzumab and CHOP in T-cell Lymphoma (ACT-1)

Lymphoma, T-Cell, Peripheral

Norway, Belgium, Finland, Denmark, Austria, Czechia, Portugal, Germany, Netherlands, Poland, Sweden
Therapeutic Advances in Childhood Leukemia Consortium
GlaxoSmithKline; Novartis

Terminated

Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL

Relapsed T-Cell Acute Lymphoblastic Leukemia | Relapsed T-Cell Lymphoblastic Lymphoma

United States, France, Canada, Australia, Austria, Italy, Netherlands
Wugen, Inc.

Recruiting

A Phase 1/2 Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL

Lymphoblastic Lymphoma | T-cell Acute Lymphoblastic Leukemia

United States, Australia, Netherlands, France
Princess Maxima Center for Pediatric Oncology
Innovative Therapies For Children with Cancer Consortium; IBFM; Fight Kids Cancer

Not yet recruiting

HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (HEM-iSMART B)

Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory | Lymphoblastic...

Netherlands
Princess Maxima Center for Pediatric Oncology
Innovative Therapies For Children with Cancer Consortium; IBFM; Fight Kids Cancer

Not yet recruiting

HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (HEM-iSMART C)

Acute Lymphoblastic Leukemia, in Relapse | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

Netherlands
Princess Maxima Center for Pediatric Oncology
Innovative Therapies For Children with Cancer Consortium; IBFM; Fight Kids Cancer

Not yet recruiting

HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (HEM-iSMART A)

Acute Lymphoblastic Leukemia, in Relapse | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

Netherlands
Princess Maxima Center for Pediatric Oncology
Innovative Therapies For Children with Cancer Consortium; IBFM; Fight Kids Cancer

Not yet recruiting

HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies (HEM-iSMART D)

Acute Lymphoblastic Leukemia, in Relapse | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

Netherlands
Princess Maxima Center for Pediatric Oncology
Takeda

Recruiting

Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors (Briga-PED)

Anaplastic Large Cell Lymphoma, ALK-Positive | Inflammatory Myofibroblastic Tumor | Other Solid Tumor

France, Netherlands
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Precursor Cell Lymphoblastic Leukemia-Lymphoma

United States, United Kingdom, France, Sweden, Germany, Spain, Italy, Belgium, Israel, Netherlands
UMC Utrecht
Julius Clinical

Not yet recruiting

Mitochondrial dysfUnction: a Key Player in Doxorubicin-induced Skeletal and Cardiac muscLE Damage (MUSCLE)

B-cell Lymphoma | Chemotherapeutic Toxicity | T-cell Lymphoma | Doxorubicin Induced Cardiomyopathy

Netherlands
Eisai Inc.

Completed

Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients

Lymphoma, T-Cell, Cutaneous | Mycosis Fungoides | Sezary Syndrome

Germany, Canada, United Kingdom, Austria, Russian Federation, United States, Australia, Poland, Switzerland, Netherlands
AstraZeneca

Completed

Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | Chronic Myelomonocytic Leukemia | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | High Risk Myelodysplastic Syndrome | Small Lymphocytic Lymphoma | B-cell Non-Hodgkin Lymphoma | Richter's Syndrome | T-cell Non-Hodgkin Lymphoma | Relapsed or Refractory...

United Kingdom, Germany, Netherlands
Gustave Roussy, Cancer Campus, Grand Paris

Completed

Combination Chemotherapy in Treating Children With Anaplastic Large Cell Lymphoma (ALCL 99) (ALCL 99)

Lymphoma

France, Spain, Italy, Belgium, Germany, Switzerland, Austria, United Kingdom, Netherlands, Sweden
European Organisation for Research and Treatment...

Terminated

Ultraviolet Light Therapy Using Methoxsalen With or Without Bexarotene in Treating Patients With Mycosis Fungoides

Lymphoma

Spain, Finland, France, Germany, Switzerland, Belgium, Netherlands, Italy, Israel, Denmark, Hungary, United Kingdom, Austria
Gustave Roussy, Cancer Campus, Grand Paris

Recruiting

Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2) (NIVO-ALCL)

Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma

France, Denmark, Netherlands
AbbVie

Completed

A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia

Leukemia | Cancer | T-cell Prolymphocytic Leukemia (T-PLL)

United States, Australia, Austria, Finland, France, Germany, Italy, Netherlands, United Kingdom
Millennium Pharmaceuticals, Inc.

Completed

Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma

Relapsed or Refractory Hodgkin Lymphoma | Relapsed or Refractory Anaplastic Large-cell Lymphoma

United States, France, United Kingdom, Germany, Spain, Netherlands, Italy, Mexico
Kyowa Kirin Pharmaceutical Development Ltd

Recruiting

Real World Observational Study of Poteligeo in Adult Patients With MF and SS (PROSPER) (PROSPER)

Mycosis Fungoides and Sézary Syndrome

Spain, United Kingdom, Netherlands, United States, Italy
4SC AG

Active, not recruiting

Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) (RESMAIN)

Lymphoma, T-Cell, Cutaneous | Mycosis Fungoides | Sezary Syndrome

Austria, Spain, Germany, United Kingdom, France, Belgium, Japan, Switzerland, Italy, Poland, Netherlands, Greece
European Inter-group Cooperation on Childhood and...

Unknown

Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma

Lymphoma

France, United Kingdom, Germany, Italy, Belgium, Switzerland, Austria, Czech Republic, Ireland, Netherlands, Poland, Sweden
Stichting Hemato-Oncologie voor Volwassenen Nederland

Recruiting

Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse (HOVON 136 NHL)

DLBCL

Netherlands
University Medical Center Groningen
Hoffmann-La Roche; Amsterdam UMC, location VUmc; Stichting Hemato-Oncologie voor...

Withdrawn

Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution in Lymphoma Patients

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

Netherlands
University Medical Center Groningen

Recruiting

PD-L1 PET-imaging During CAR T-cell Therapy

Large B-cell Lymphoma

Netherlands
Gustave Roussy, Cancer Campus, Grand Paris
Children's Oncology Group

Unknown

Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients

B-cell Non Hodgkin Lymphoma | Mature B-cell Leukemia Burkitt-type

Belgium, France, United Kingdom, Netherlands, Canada, Hungary, Italy, Poland, Spain, China
University Medical Center Groningen
Stichting Hemato-Oncologie voor Volwassenen Nederland

Recruiting

Comparison of Point-of-care Produced CAR T-cell With Commercial CAR T-cells in Patients With R/R LBCL (HOVON161)

NHL | DLBCL - Diffuse Large B Cell Lymphoma

Netherlands
Nurix Therapeutics, Inc.

Recruiting

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Mantle Cell Lymphoma (MCL) | Follicular Lymphoma (FL) | Primary Central Nervous System Lymphoma (PCNSL) | Marginal Zone Lymphoma (MZL) | Waldenstrom Macroglobulinemia (WM) | Diffuse Large B Cell Lymphoma (DLBCL)

United States, United Kingdom, Netherlands
Genentech, Inc.

Completed

A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma

Chronic Lymphocytic Leukemia | Non-Hodgkins Lymphoma

United States, France, Canada, Netherlands
Genmab
AbbVie

Terminated

First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Small Lymphocytic Lymphoma | High-grade B-cell Lymphoma | Primary Mediastinal Large B-cell Lymphoma

United States, Spain, Netherlands, Belgium, France, Denmark
Children's Oncology Group
National Cancer Institute (NCI); EsPhALL Network/ BFM Study Group

Recruiting

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | T Acute Lymphoblastic Leukemia | Mixed Phenotype Acute Leukemia

United States, Canada, Puerto Rico, Australia, Finland, New Zealand, Saudi Arabia, Germany, Austria, Belgium, Chile, Czechia, France, Italy, Netherlands, Sweden, Switzerland, Hong Kong, Israel
Celgene

Completed

A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)

Lymphoma, Non-Hodgkin | Precursor Cell Lymphoblastic Leukemia-Lymphoma

Spain, Netherlands, United States, France, Germany, Italy
The Netherlands Cancer Institute
Dutch Cancer Society

Completed

To Decrease Fatigue With Light Therapy (SPARKLE)

Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma

Netherlands
Medigene AG

Withdrawn

HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Myeloproliferative Disorders | Multiple Myeloma | Myelofibrosis | Chronic Myeloid Leukemia | Acute Lymphoid Leukemia | Malignant Lymphoma

Netherlands
medac GmbH

Completed

Comparative Efficacy and Safety of Two Asparaginase Preparations in Children With Previously Untreated Acute Lymphoblastic Leukaemia

Acute Lymphoblastic Leukemia

Netherlands
TG Therapeutics, Inc.

Terminated

Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma (UNITY-NHL)

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Small Lymphocytic Lymphoma

United States, Poland, Australia, Italy, United Kingdom, Israel, Korea, Republic of, Slovakia, Spain
Kite, A Gilead Company

Recruiting

Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ZUMA-4)

Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Spain, United States, Canada, Belgium, Poland, Czechia, Italy, France, Germany, Netherlands, Sweden
medac GmbH

Completed

Efficacy and Safety of Recombinant Asparaginase in Infants With Previously Untreated Acute Lymphoid Leukemia (ALL)

Acute Lymphoid Leukemia

Germany, Netherlands
Gustave Roussy, Cancer Campus, Grand Paris
Children's Oncology Group

Active, not recruiting

Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation

Primary Mediastinal Large B Cell Lymphoma

France, Belgium, United Kingdom, Netherlands, Canada, Hungary, Italy, Poland, Spain
Kite, A Gilead Company

Recruiting

Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma

Relapsed and/or Refractory B-cell Lymphoma

United States, Netherlands, United Kingdom, Germany
Genmab
AbbVie

Active, not recruiting

First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma (EPCORE™ NHL-1)

Small Lymphocytic Lymphoma (SLL) | DLBCL | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | MCL | Marginal Zone Lymphoma (MZL) | High-grade B-cell Lymphoma (HGBCL) | FL

Korea, Republic of, United States, Australia, Singapore, Netherlands, Sweden, France, Finland, United Kingdom, Spain, Germany, Denmark, Italy, Poland, Canada

Clinical Trials on Peripheral T/NK-cell Lymphoma in Netherlands

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Equatorial Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations